Literature DB >> 23809508

Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: a reconsideration.

Drucy Borowitz1, Daniel Gelfond, Karen Maguiness, James E Heubi, Bonnie Ramsey.   

Abstract

The current recommendations for dosing of pancreatic enzyme replacement therapy (PERT) in infants with cystic fibrosis (CF) were made using a limited evidence base. The per meal recommended dose was extrapolated from dosing guidelines for older patients into a maximal daily dose for infants. We discuss why this maximal daily dose recommendation may be insufficient for young infants with CF, although the optimal dose of PERT for infants with CF remains unknown.
Copyright © 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Infant nutrition; Pancreatic enzymes; Pancreatic insufficiency

Mesh：

Substances：

Year:  2013        PMID： 23809508     DOI： 10.1016/j.jcf.2013.05.011

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN： 1569-1993            Impact factor:   5.482


  8 in total

1.  Pancreatic Enzyme Replacement Therapy Use in Infants With Cystic Fibrosis Diagnosed by Newborn Screening.

Authors:  Daniel Gelfond; Sonya L Heltshe; Michelle Skalland; James E Heubi; Margaret Kloster; Daniel H Leung; Bonnie W Ramsey; Drucy Borowitz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-04       Impact factor: 2.839

2.  Impact of guideline-recommended dietitian assessments on weight gain in infants with cystic fibrosis.

Authors:  Thida Ong; Frankline M Onchiri; Maria T Britto; Sonya L Heltshe; Larry G Kessler; Michael Seid; Bonnie W Ramsey
Journal:  J Cyst Fibros       Date:  2021-08-26       Impact factor: 5.482

3.  Innovative approach for self-management and social welfare of children with cystic fibrosis in Europe: development, validation and implementation of an mHealth tool (MyCyFAPP).

Authors:  Joaquim Calvo-Lerma; Celia P Martinez-Jimenez; Juan-Pablo Lázaro-Ramos; Ana Andrés; Paula Crespo-Escobar; Erlend Stav; Cornelia Schauber; Lucia Pannese; Jessie M Hulst; Lucrecia Suárez; Carla Colombo; Celeste Barreto; Kris de Boeck; Carmen Ribes-Koninckx
Journal:  BMJ Open       Date:  2017-03-16       Impact factor: 2.692

4.  User Needs in the Development of a Health App Ecosystem for Self-Management of Cystic Fibrosis: User-Centered Development Approach.

Authors:  Jacqueline Floch; Annabel Zettl; Lena Fricke; Tina Weisser; Lisbet Grut; Thomas Vilarinho; Erlend Stav; Antonio Ascolese; Cornelia Schauber
Journal:  JMIR Mhealth Uhealth       Date:  2018-05-08       Impact factor: 4.773

5.  Relationship of Initial Pancreatic Enzyme Replacement Therapy Dose With Weight Gain in Infants With Cystic Fibrosis.

Authors:  Michael S Schechter; Suzanne Michel; Shufang Liu; B Woun Seo; Mudra Kapoor; Rupal Khurmi; Mark Haupt
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-10       Impact factor: 2.839

Review 6.  Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis.

Authors:  Peter N Freswick; Elizabeth K Reid; Maria R Mascarenhas
Journal:  Nutrients       Date:  2022-03-23       Impact factor: 5.717

Review 7.  Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis.

Authors:  Christabella Ng; Giles Major; Alan R Smyth
Journal:  Cochrane Database Syst Rev       Date:  2021-08-02

8.  Users' Experiences of a Mobile Health Self-Management Approach for the Treatment of Cystic Fibrosis: Mixed Methods Study.

Authors:  Jacqueline Floch; Thomas Vilarinho; Annabel Zettl; Gema Ibanez-Sanchez; Joaquim Calvo-Lerma; Erlend Stav; Peter Halland Haro; Asbjørn Lein Aalberg; Alvaro Fides-Valero; José Luis Bayo Montón
Journal:  JMIR Mhealth Uhealth       Date:  2020-07-08       Impact factor: 4.773
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.